Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OSE Immunotherapeutics
The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.
OSE’s late-stage ambitions for Tedopi were stalled by the pandemic but the Nantes-based firm has now requested a meeting with the US FDA to get the Phase III program for the anticancer vaccine back on track.
While many of his peers elbowed each other to leap into oncology, James Xue decided to focus on rare diseases such as Hunter’s Syndrome. Now, 10 years after founding CANbridge, the CEO sat down for an audio interview with Scrip to offer his views on a flurry of key issues impacting orphan drug development in potentially the world's largest pharma market.
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
- Large Molecule
- Other Names / Subsidiaries
- Biotech Synergy
- Effimune SA
- Orphan Synergy Europe Pharma
- OSE Pharma
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.